ArticleBMC nephrology2026
Cost-utility analysis of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression in patients with type 2 diabetes mellitus.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany trials have highlighted the benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in terms of chronic kidney disease (CKD) progression. However, SGLT2is are high-cost medication, and their cost- effectiveness varies by setting across countries.
methodsThis study aimed to evaluate the cost-effectiveness of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in terms of chronic kidney disease (CKD) progression by utilizing data from the type 2 diabetes mellitus (T2D) cohort collected from 2010 to 2022 to estimate transitional probabilities and costs. Markov models were constructed from the following states: CKD stage 3, 4, 5, and death. Cost and quality-adjusted life year (QALY) were estimated for SGLT2i and non-SGLT2i groups from both hospital and societal perspectives.
resultsFrom a societal perspective, the incremental cost was US$3,485.28 (US$80,245.48 (non-SGLT2i) and US$83,730.76 (SGLT2i)), and US$2,971.00 (US$80,913.73 (non-SGLT2i) and US$83,884.73 (SGLT2i)) in patients with renal replacement therapy (RRT) and without RRT, respectively. The incremental QALY were 2.73 (13.88 (non-SGLT2i) and 16.61 years (SGLT2i)) and 2.79 years (13.78 (non-SGLT2i) and 16.57 years (SGLT2i)) in patients with RRT and without RRT, respectively. ICERs were US$1,276.66 and US$1,064.87 per QALY in patients with and without RRT, respectively. A one-way sensitivity analysis suggested that the admission cost per day had the biggest impact on the ICER. Although SGLT2is are more expensive than alternatives, they remain cost-effective at the Thai willingness to pay threshold of US$4,869 per QALY.
conclusionThis finding was robust in multiple sensitivity analyses, showing consistent net benefit regardless of RRT status. Future research should now focus on differentiating the value of specific drugs within the class. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.